National Cancer Institute (NCI): Meningioma trials

The registry lists 18 Meningioma studies with National Cancer Institute (NCI) as lead sponsor. 0 are open to participants now and 5 have results posted.

Phase 1 14Phase 2 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS CancersTerminatedNCT03173950Phase 2Results posted
• T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing CancerCompletedNCT01967823Phase 2Results posted
• Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck CancerCompletedNCT00492089Phase 2Results posted
• Imatinib Mesylate in Treating Patients With Recurrent MeningiomaCompletedNCT00045734Phase 2Results posted
• Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive MeningiomaCompletedNCT00045110Phase 1/2Results posted
• Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III MeningiomaActive, not recruitingNCT03604978Phase 1/2
• RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant GliomaCompletedNCT01119599Phase 1
• Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell LeukemiaTerminatedNCT01088763Phase 1
• Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord TumorsCompletedNCT01076530Phase 1
• Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and LymphomaCompletedNCT00994500Phase 1
• ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS TumorsCompletedNCT00946335Phase 1
• Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or LymphomaCompletedNCT00363272Phase 1
• AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS TumorsCompletedNCT00326664Phase 1
• Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain TumorsTerminatedNCT00110032Phase 1
• Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS TumorsCompletedNCT00100880Phase 1
• Cilengitide in Treating Children With Refractory Primary Brain TumorsCompletedNCT00063973Phase 1
• FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or LeukemiaCompletedNCT00053963Phase 1
• Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain TumorsCompletedNCT00052780Phase 1